Join the U.S. Progress Point Subscribers' Circle
First looks, exclusive content, and more.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Life Sciences Solutions
-
Healthcare Solutions
-
Medical Device and Diagnostic
-
U.S. Government
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences Solutions
Healthcare Solutions
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreHealthcare Solutions
Medical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreMedical Device and Diagnostic Solutions
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreU.S. Government Solutions
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREInsight Brief
Launch Excellence, U.S. Edition: The Rewrite of the Business of Launch
The very lifeblood of pharma is undergoing a success transformation, commanding new metrics to reach new heights
Mar 05, 2024
Today, a successful launch is no longer defined by just dollars — it's defined by the number of patients reached, acquired, and retained. To reflect this new reality, we've refined our take on the modern launch, and carefully considered what needs to change to achieve commercial success in a pressurized environment.
New data, metrics, and understanding of patient behavior and what drives patient acquisition indicate we need to think about launch differently to maximize value – and treat as many patients as possible. In this paper, IQVIA experts discuss the clear need for a rewrite of the modern launch playbook.
New data, metrics, and understanding of patient behavior and what drives patient acquisition indicate we need to think about launch differently to maximize value – and treat as many patients as possible. In this paper, IQVIA experts discuss the clear need for a rewrite of the modern launch playbook.
Related solutions
How Will We Remember This Moment? An Alzheimer's Perspective
The second disease-modifying Alzheimer's treatment is here with more on the horizon, but is the healthcare ecosystem ready for their impact?
Mounjaro: A New Era of Preventive Care and Consumer Health
An analysis of Mounjaro's stand-out market performance and the shifts it signals in U.S. healthcare
See The Whole Board
The Inflation Reduction Act of 2022, and the complex chess game now in play for pharmaceutical manufacturers
A Foreword — Their Finest Hour: Medical Affairs in a Disrupted World
From the U.S. Progress Point Editorial Board